

(19)



(11)

**EP 3 618 853 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**09.09.2020 Bulletin 2020/37**

(51) Int Cl.:  
**A61K 38/36<sup>(2006.01)</sup> A61P 31/00<sup>(2006.01)</sup>**  
**A61P 31/04<sup>(2006.01)</sup> A61P 31/10<sup>(2006.01)</sup>**

(21) Application number: **19722534.5**

(86) International application number:  
**PCT/EP2019/060546**

(22) Date of filing: **24.04.2019**

(87) International publication number:  
**WO 2019/207016 (31.10.2019 Gazette 2019/44)**

**(54) FIBRINOGEN GAMMA PRIME VARIANTS FOR USE IN TREATING AN INFECTION**

THERAPEUTISCHE VERWENDUNGEN VON FIBRINOGEN-GAMMA-PRIME-VARIANTEN

VARIANTS DE GAMMA PRIME DE FIBRINOGENÈNE POUR L'UTILISATION DANS LE TRAITEMENT D'UNE INFECTION

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(74) Representative: **Ringeling, Patricia Louise Enelex Innovation BV Van der Lelijstraat 8 2614 EM Delft (NL)**

(30) Priority: **24.04.2018 EP 18168993**  
**24.04.2018 EP 18168996**

(56) References cited:  
**WO-A2-2010/005513 US-A1- 2011 171 285**

(43) Date of publication of application:  
**11.03.2020 Bulletin 2020/11**

- **VANNAKAMBADI K GANESH ET AL: "A Structural Model of the Staphylococcus aureus ClfA?Fibrinogen Interaction Opens New Avenues for the Design of Anti-Staphylococcal Therapeutics", PL O S PATHOGENS (PRINT), PUBLIC LIBRARY OF SCIENCE, US, vol. 4, no. 11, 28 November 2008 (2008-11-28), pages 1-10, XP007915427, ISSN: 1553-7366, DOI: 10.1371/JOURNAL.PPAT.1000226**
- **J Hawiger: "Interaction of human fibrinogen with staphylococci: presence of a binding region on normal and abnormal fibrinogen variants and fibrinogen derivatives.", Blood, 1 May 1978 (1978-05-01), XP055505829, Retrieved from the Internet: URL: <http://www.ncbi.nlm.nih.gov/pubmed/25098> [retrieved on 2018-09-10]**

(73) Proprietor: **Fibriant B.V. 2333 CG Leiden (NL)**

- (72) Inventors:
- **WEGGEMAN, Miranda 2333 CG Leiden (NL)**
  - **GRIMBERGEN, Joseph 2333 CG Leiden (NL)**
  - **KOOPMAN, Jacob 2333 CG Leiden (NL)**

**EP 3 618 853 B1**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).